GU ONCOLOGY

Browse all GU ONCOLOGY
Refining the Post-IO Strategy in mRCC: The Role of TKIs and the Nuance of Timing

GU ONCOLOGY

Refining the Post-IO Strategy in mRCC: The Role of TKIs and the Nuance of Timing

Karan Jatwani, MD, Urvi Patel, DO, MPH

The Evolving Landscape of Refractory Renal Cell Carcinoma 

GU ONCOLOGY

The Evolving Landscape of Refractory Renal Cell Carcinoma 

Michael Serzan, MD

TKIs After Upfront Immunotherapy in Metastatic RCC: A Practical Review

GU ONCOLOGY

TKIs After Upfront Immunotherapy in Metastatic RCC: A Practical Review

Brendan Guercio, MD

GI ONCOLOGY

Browse all GI ONCOLOGY
Over The Counter Medication: A Game-Changer for PI3K-Altered Colorectal Cancer?

GI ONCOLOGY

Over The Counter Medication: A Game-Changer for PI3K-Altered Colorectal Cancer?

Sawyer Bawek, DO

HEMATOLOGY

Browse all HEMATOLOGY
MajesTEC-9: Teclistamab Monotherapy Delivers Survival Benefits in Early Relapsed/Refractory Multiple Myeloma

HEMATOLOGY

MajesTEC-9: Teclistamab Monotherapy Delivers Survival Benefits in Early Relapsed/Refractory Multiple Myeloma

Sawyer Bawek, DO

Year in Review: The Rise of Cellular Immunotherapy for Multiple Myeloma

HEMATOLOGY

Year in Review: The Rise of Cellular Immunotherapy for Multiple Myeloma

Hamza Hashmi, MD

Real-World Evidence Supports Outpatient Axicabtagene Ciloleucel (Yescarta) Administration for Relapsed/Refractory LBCL

HEMATOLOGY

Real-World Evidence Supports Outpatient Axicabtagene Ciloleucel (Yescarta) Administration for Relapsed/Refractory LBCL

Sawyer Bawek, DO

The Impact of Novel Agents in Non-Hodgkin Lymphoma Treatment

HEMATOLOGY

The Impact of Novel Agents in Non-Hodgkin Lymphoma Treatment

Anuja V. Abhyankar, MD

LUNG CANCER

Browse all LUNG CANCER
Beyond Osimertinib Monotherapy: Frontline Intensification in EGFR-Mutant NSCLC After FLAURA2 and MARIPOSA

LUNG CANCER

Beyond Osimertinib Monotherapy: Frontline Intensification in EGFR-Mutant NSCLC After FLAURA2 and MARIPOSA

Chinmay Jani, MD, Ruchi Jani, Gilberto Lopes, MD

Top Lung Cancer Advances From 2025

LUNG CANCER

Top Lung Cancer Advances From 2025

Chinmay Jani, MD, Ali Al Sbihi, MD, Gilberto Lopes, MD

Ivonescimab Plus Chemotherapy in EGFR+ NSCLC After TKI Therapy

LUNG CANCER

Ivonescimab Plus Chemotherapy in EGFR+ NSCLC After TKI Therapy

Ali Al Sbihi, MD, Chinmay Jani, MD

IMforte Trial: A Potential First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

LUNG CANCER

IMforte Trial: A Potential First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Sawyer Bawek, DO